Heat Biologics, Inc. Viagenpumatucel -L Protocol HS110 -102 CONFIDENTIAL Amendment 6, 24 May 2019 Page 1 of 95 CLINICAL PROTOCOL A PHASE 1B/2 STUDY O F VIAGENPUMATUCEL‑L (HS-110) IN COMBINATION WITH MULTIPLE TREATM ENT REGIMENS IN PATI ENTS WITH NON‑SMALL CELL LUNG CANCER (TH E “DURGA” TRIAL) Protocol Number: HS110 -102 Version and Date: Amendment #6, 24 May 2019 Previous Versions: Amendment #5, 05 September 2018 Amendment #4, 07 December 2017 Amendment #3, 21 November 2016 Amendment #2, 11 December 2015 Amendment #1, 02 July 2015 Initial Protocol, 30 December 2014 Investigational Product: Viagenpumatucel -L (HS -110) IND Number: 14814 Indication: Non-Small Cell Lung Cancer (NSCLC) Develo pment Phase: 1b/2 Principal Investigator: Daniel Morgensztern, MD Sponsor: Heat Biologics, Inc. 801 Capitola Drive, Suite 12 Durham, NC 27713 Tel: +1 -919- 794-7914 CONFIDENTIAL & PROPRIETARY Information in this document is confidential and should not be disclosed without the written consent of Heat Biolo gics, Inc.